References
1. D'Amico G, Garcia-Tsao G, Pagliaro L. Natural history and prognostic indicators of survival in cirrhosis: a systematic review of 118 studies. J Hepatol. 2006 Jan;44(1):217-31. doi: 10.1016/j.jhep.2005.10.013. Epub 2005 Nov 9. PMID: 16298014.
2. de Franchis R; Baveno VI Faculty. Expanding consensus in portal hypertension: Report of the Baveno VI Consensus Workshop: Stratifying risk and individualizing care for portal hypertension. J Hepatol. 2015 Sep;63(3):743-52. doi: 10.1016/j.jhep.2015.05.022. Epub 2015 Jun 3. PMID: 26047908.
3. de Franchis R, Bosch J, Garcia-Tsao G, Reiberger T, Ripoll C; Baveno VII Faculty. Baveno VII - Renewing consensus in portal hypertension. J Hepatol. 2021 Dec 30:S0168-8278(21)02299-6. doi: 10.1016/j.jhep.2021.12.022. Epub ahead of print. PMID: 35120736.
4. Groszmann RJ, Garcia-Tsao G, Bosch J, Grace ND, Burroughs AK, et al. Beta-blockers to prevent gastroesophageal varices in patients with cirrhosis. N Engl J Med. 2005 Nov 24;353(21):2254-61. doi: 10.1056/NEJMoa044456. PMID: 16306522.
5. Ripoll C, Groszmann R, Garcia-Tsao G, Grace N, Burroughs A, Planas R, et al. Hepatic venous pressure gradient predicts clinical decompensation in patients with compensated cirrhosis. Gastroenterology. 2007 Aug;133(2):481-8. doi: 10.1053/j.gastro.2007.05.024. Epub 2007 May 21. PMID: 17681169.
6. Pomier-Layrargues G, Kusielewicz D, Willems B, Villeneuve JP, Marleau D, Côté J, et al. Presinusoidal portal hypertension in non-alcoholic cirrhosis. Hepatology. 1985 May-Jun;5(3):415-8. doi: 10.1002/hep.1840050312. PMID: 3997071.
7. Bassegoda O, Olivas P, Turco L, Mandorfer M, Serra-Burriel M, Tellez L et al. Decompensation in Advanced Nonalcoholic Fatty Liver Disease May Occur at Lower Hepatic Venous Pressure Gradient Levels Than in Patients With Viral Disease. Clin Gastroenterol Hepatol. 2021 Oct 21:S1542-3565(21)01136-8. doi: 10.1016/j.cgh.2021.10.023. Epub ahead of print. PMID: 34688952.
8. Silva-Junior G, Baiges A, Turon F, Torres F, Hernández-Gea V, Bosch J, et al. The prognostic value of hepatic venous pressure gradient in patients with cirrhosis is highly dependent on the accuracy of the technique. Hepatology. 2015 Nov;62(5):1584-92. doi: 10.1002/hep.28031. Epub 2015 Sep 30. PMID: 26238376.
9. Zhang W, Peng C, Zhang S, Huang S, Shen S, Xu G, et al. EUS-guided portal pressure gradient measurement in patients with acute or subacute portal hypertension. Gastrointest Endosc. 2021 Mar;93(3):565-572. doi: 10.1016/j.gie.2020.06.065. Epub 2020 Jun 29. PMID: 32615178.
10. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; Clinical Practice Guideline Panel; Chair:; EASL Governing Board representative:; Panel members:. EASL Clinical Practice Guidelines on non-invasive tests for evaluation of liver disease severity and prognosis - 2021 update. J Hepatol. 2021 Sep;75(3):659-689. doi: 10.1016/j.jhep.2021.05.025. Epub 2021 Jun 21. PMID: 34166721.
11.
12. Pons M, Rodríguez-Tajes S, Esteban JI, Mariño Z, Vargas V, Lens S, et al. Non-invasive prediction of liver-related events in patients with HCV-associated compensated advanced chronic liver disease after oral antivirals. J Hepatol. 2020 Mar;72(3):472-480. doi: 10.1016/j.jhep.2019.10.005. Epub 2019 Oct 17. PMID: 31629779.
13. Semmler G, Binter T, Kozbial K, Schwabl P, Hametner-Schreil S, Zanetto A, et al. Noninvasive Risk Stratification After HCV Eradication in Patients With Advanced Chronic Liver Disease. Hepatology. 2021 Apr;73(4):1275-1289. doi: 10.1002/hep.31462. Epub 2021 Mar 16. PMID: 32659847; PMCID: PMC8252110.
14. Petta S, Sebastiani G, Viganò M, Ampuero J, Wai-Sun Wong V, Boursier J, et al. Monitoring Occurrence of Liver-Related Events and Survival by Transient Elastography in Patients With Nonalcoholic Fatty Liver Disease and Compensated Advanced Chronic Liver Disease. Clin Gastroenterol Hepatol. 2021 Apr;19(4):806-815.e5. doi: 10.1016/j.cgh.2020.06.045. Epub 2020 Jul 2. PMID: 32621970.
15. Vuille-Lessard É, Rodrigues SG, Berzigotti A. Noninvasive Detection of Clinically Significant Portal Hypertension in Compensated Advanced Chronic Liver Disease. Clin Liver Dis. 2021 May;25(2):253-289. doi: 10.1016/j.cld.2021.01.005. PMID: 33838850.
16. Pons M, Augustin S, Scheiner B, Guillaume M, Rosselli M, Rodrigues SG, et al. Noninvasive Diagnosis of Portal Hypertension in Patients With Compensated Advanced Chronic Liver Disease. Am J Gastroenterol. 2021 Apr;116(4):723-732. doi: 10.14309/ajg.0000000000000994. PMID: 33982942.
17. Abraldes JG, Bureau C, Stefanescu H, Augustin S, Ney M, Blasco H, et al. Noninvasive tools and risk of clinically significant portal hypertension and varices in compensated cirrhosis: The "Anticipate" study. Hepatology. 2016 Dec;64(6):2173-2184. doi: 10.1002/hep.28824. Epub 2016 Oct 27. Erratum in: Hepatology. 2017 Jul;66(1):304-305. PMID: 27639071.
18. Stefanescu H, Marasco G, Calès P, Fraquelli M, Rosselli M, Ganne-Carriè N, et al. A novel spleen-dedicated stiffness measurement by FibroScan® improves the screening of high-risk oesophageal varices. Liver Int. 2020 Jan;40(1):175-185. doi: 10.1111/liv.14228. Epub 2019 Sep 11. PMID: 31444849.
19. Wang H, Wen B, Chang X, Wu Q, Wen W, Zhou F et al. Baveno VI criteria and spleen stiffness measurement rule out high-risk varices in virally suppressed HBV-related cirrhosis. J Hepatol. 2021 Mar;74(3):584-592. doi: 10.1016/j.jhep.2020.09.034. Epub 2020 Oct 8. PMID: 33039403.
20. Zykus R, Jonaitis L, Petrenkienė V, Pranculis A, Kupčinskas L. Liver and spleen transient elastography predicts portal hypertension in patients with chronic liver disease: a prospective cohort study. BMC Gastroenterol. 2015 Dec 24;15:183. doi: 10.1186/s12876-015-0414-z. Erratum in: BMC Gastroenterol. 2016;16(1):53. PMID: 26702818; PMCID: PMC4690243.
21. Vorobioff J, Groszmann RJ, Picabea E, Gamen M, Villavicencio R, Bordato J, Morel I, Audano M, Tanno H, Lerner E, Passamonti M. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: a 10-year prospective study. Gastroenterology. 1996 Sep;111(3):701-9. doi: 10.1053/gast.1996.v111.pm8780575. PMID: 8780575.
22. Lackner C, Spindelboeck W, Haybaeck J, Douschan P, Rainer F, Terracciano L, et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. J Hepatol. 2017 Mar;66(3):610-618. doi: 10.1016/j.jhep.2016.11.011. Epub 2016 Nov 25. PMID: 27894795.
23. Thabut D, Bureau C, Layese R, Bourcier V, Hammouche M, Cagnot C, et al. Validation of Baveno VI Criteria for Screening and Surveillance of Esophageal Varices in Patients With Compensated Cirrhosis and a Sustained Response to Antiviral Therapy. Gastroenterology. 2019 Mar;156(4):997-1009.e5. doi: 10.1053/j.gastro.2018.11.053. Epub 2019 Feb 13. PMID: 30768988.
24. Spahr L, Goossens N, Furrer F, Dupuis M, Vijgen S, Elkrief L, et al. A return to harmful alcohol consumption impacts on portal hemodynamic changes following alcoholic hepatitis. Eur J Gastroenterol Hepatol. 2018 Aug;30(8):967-974. doi: 10.1097/MEG.0000000000001148. PMID: 29727387.
25. Manolakopoulos S, Triantos C, Theodoropoulos J, Vlachogiannakos J, Kougioumtzan A, Papatheodoridis G, et al. Antiviral therapy reduces portal pressure in patients with cirrhosis due to HBeAg-negative chronic hepatitis B and significant portal hypertension. J Hepatol. 2009 Sep;51(3):468-74. doi: 10.1016/j.jhep.2009.05.031. Epub 2009 Jul 3. PMID: 19616339.
26. Lens S, Baiges A, Alvarado-Tapias E, LLop E, Martinez J, Fortea JI, et al. Clinical outcome and hemodynamic changes following HCV eradication with oral antiviral therapy in patients with clinically significant portal hypertension. J Hepatol. 2020 Dec;73(6):1415-1424. doi: 10.1016/j.jhep.2020.05.050. Epub 2020 Jun 12. PMID: 32535060.
27. Mandorfer M, Kozbial K, Schwabl P, Chromy D, Semmler G, Stättermayer AF, et al. Changes in Hepatic Venous Pressure Gradient Predict Hepatic Decompensation in Patients Who Achieved Sustained Virologic Response to Interferon-Free Therapy. Hepatology. 2020 Mar;71(3):1023-1036. doi: 10.1002/hep.30885. Epub 2019 Oct 14. PMID: 31365764; PMCID: PMC7155089.
28. Tosetti G, Degasperi E, Farina E, D'Ambrosio R, Soffredini R, Borghi M, et al. Decompensation in Direct-Acting Antiviral Cured Hepatitis C Virus Compensated Patients With Clinically Significant Portal Hypertension: Too Rare to Warrant Universal Β-Blocker Therapy. Am J Gastroenterol. 2021 Jun 1;116(6):1342-1344. doi: 10.14309/ajg.0000000000001158. PMID: 33606382.
29. European Association for the Study of the Liver. Electronic address: easloffice@easloffice.eu; European Association for the Study of the Liver. EASL Clinical Practice Guidelines for the management of patients with decompensated cirrhosis. J Hepatol. 2018 Aug;69(2):406-460. doi: 10.1016/j.jhep.2018.03.024. Epub 2018 Apr 10.
30. Garcia-Tsao G, Abraldes JG, Berzigotti A, Bosch J. Portal hypertensive bleeding in cirrhosis: Risk stratification, diagnosis, and management: 2016 practice guidance by the American Association for the study of liver diseases. Hepatology. 2017 Jan;65(1):310-335. doi: 10.1002/hep.28906. Epub 2016 Dec 1.
31. D'Amico G, Pagliaro L, Bosch J. Pharmacological treatment of portal hypertension: an evidence-based approach. Semin Liver Dis. 1999;19(4):475-505. doi: 10.1055/s-2007-1007133. Erratum in: Semin Liver Dis 2000;20(3):399. PMID: 10643630.
32. Villanueva C, Albillos A, Genescà J, Abraldes JG, Calleja JL, Aracil C, Bañares R, Morillas R, Poca M, Peñas B, Augustin S, Garcia-Pagan JC, Pavel O, Bosch J. Development of hyperdynamic circulation and response to β-blockers in compensated cirrhosis with portal hypertension. Hepatology. 2016 Jan;63(1):197-206. doi: 10.1002/hep.28264. Epub 2015 Nov 26. PMID: 26422126.
33. Villanueva C, Albillos A, Genescà J, Garcia-Pagan JC, Calleja JL, Aracil C, et al. β blockers to prevent decompensation of cirrhosis in patients with clinically significant portal hypertension (PREDESCI): a randomised, double-blind, placebo-controlled, multicentre trial. Lancet. 2019 Apr 20;393(10181):1597-1608. doi: 10.1016/S0140-6736(18)31875-0. Epub 2019 Mar 22. Erratum in: Lancet. 2019 Jun 22;393(10190):2492. PMID: 30910320.
34. Jachs M, Hartl L, Schaufler D, Desbalmes C, Simbrunner B, Eigenbauer E, et al. Amelioration of systemic inflammation in advanced chronic liver disease upon beta-blocker therapy translates into improved clinical outcomes. Gut. 2021 Sep;70(9):1758-1767. doi: 10.1136/gutjnl-2020-322712. Epub 2020 Nov 16. PMID: 33199442.
35. Senzolo M, Cholongitas E, Burra P, Leandro G, Thalheimer U, Patch D, et al. beta-Blockers protect against spontaneous bacterial peritonitis in cirrhotic patients: a meta-analysis. Liver Int. 2009 Sep;29(8):1189-93. doi: 10.1111/j.1478-3231.2009.02038.x. Epub 2009 May 1. PMID: 19508620.
36. Thiele M, Albillos A, Abazi R, Wiest R, Gluud LL, Krag A. Non-selective beta-blockers may reduce risk of hepatocellular carcinoma: a meta-analysis of randomized trials. Liver Int. 2015 Aug;35(8):2009-16. doi: 10.1111/liv.12782. Epub 2015 Feb 6. PMID: 25581713.
37. Turco L, Villanueva C, La Mura V, García-Pagán JC, Reiberger T, Genescà J, et al. Lowering Portal Pressure Improves Outcomes of Patients With Cirrhosis, With or Without Ascites: A Meta-Analysis. Clin Gastroenterol Hepatol. 2020 Feb;18(2):313-327.e6. doi: 10.1016/j.cgh.2019.05.050. Epub 2019 Jun 5. PMID: 31176013.
38. Hernández-Gea V, Aracil C, Colomo A, Garupera I, Poca M, Torras X, Miñana J, Guarner C, Villanueva C. Development of ascites in compensated cirrhosis with severe portal hypertension treated with β-blockers. Am J Gastroenterol. 2012 Mar;107(3):418-27. doi: 10.1038/ajg.2011.456. Epub 2012 Feb 14. PMID: 22334252.
39. Bañares R, Moitinho E, Matilla A, García-Pagán JC, Lampreave JL, Piera C, et al. Randomized comparison of long-term carvedilol and propranolol administration in the treatment of portal hypertension in cirrhosis. Hepatology. 2002 Dec;36(6):1367-73. doi: 10.1053/jhep.2002.36947. PMID: 12447861.
40. Sharma M, Singh S, Desai V, Shah VH, Kamath PS, Murad MH, et al. Comparison of Therapies for Primary Prevention of Esophageal Variceal Bleeding: A Systematic Review and Network Meta-analysis. Hepatology. 2019 Apr;69(4):1657-1675. doi: 10.1002/hep.30220. Epub 2019 Feb 20. PMID: 30125369.
41. Reiberger T, Ulbrich G, Ferlitsch A, Payer BA, Schwabl P, Pinter M, Heinisch BB, Trauner M, Kramer L, Peck-Radosavljevic M; Vienna Hepatic Hemodynamic Lab. Carvedilol for primary prophylaxis of variceal bleeding in cirrhotic patients with haemodynamic non-response to propranolol. Gut. 2013 Nov;62(11):1634-41. doi: 10.1136/gutjnl-2012-304038. Epub 2012 Dec 18. PMID: 23250049.
42. McDowell HR, Chuah CS, Tripathi D, Stanley AJ, Forrest EH, Hayes PC. Carvedilol is associated with improved survival in patients with cirrhosis: a long-term follow-up study. Aliment Pharmacol Ther. 2021 Feb;53(4):531-539. doi: 10.1111/apt.16189. Epub 2020 Dec 9. PMID: 33296526.
43. Gonzalez R, Zamora J, Gomez-Camarero J, Molinero LM, Bañares R, Albillos A. Meta-analysis: Combination endoscopic and drug therapy to prevent variceal rebleeding in cirrhosis. Ann Intern Med. 2008 Jul 15;149(2):109-22. doi: 10.7326/0003-4819-149-2-200807150-00007. PMID: 18626050.
44. Puente A, Hernández-Gea V, Graupera I, Roque M, Colomo A, Poca M, et al. Drugs plus ligation to prevent rebleeding in cirrhosis: an updated systematic review. Liver Int. 2014 Jul;34(6):823-33. doi: 10.1111/liv.12452. Epub 2014 Jan 24. PMID: 24373180.
45. Albillos A, Zamora J, Martínez J, Arroyo D, Ahmad I, De-la-Peña J, et al. Stratifying risk in the prevention of recurrent variceal hemorrhage: Results of an individual patient meta-analysis. Hepatology. 2017 Oct;66(4):1219-1231. doi: 10.1002/hep.29267. Epub 2017 Aug 26. PMID: 28543862; PMCID: PMC5605404.
46. Malandris K, Paschos P, Katsoula A, Manolopoulos A, Andreadis P, Sarigianni M, et al. Carvedilol for prevention of variceal bleeding: a systematic review and meta-analysis. Ann Gastroenterol. 2019 May-Jun;32(3):287-297. doi: 10.20524/aog.2019.0368. Epub 2019 Mar 12. PMID: 31040627; PMCID: PMC6479656.
47. Pérez-Ayuso RM, Piqué JM, Bosch J, Panés J, González A, Pérez R, et al. Propranolol in prevention of recurrent bleeding from severe portal hypertensive gastropathy in cirrhosis. Lancet. 1991 Jun 15;337(8755):1431-4. doi: 10.1016/0140-6736(91)93125-s. PMID: 1675316.
48. Sersté T, Melot C, Francoz C, Durand F, Rautou PE, Valla D, et al. Deleterious effects of beta-blockers on survival in patients with cirrhosis and refractory ascites. Hepatology. 2010 Sep;52(3):1017-22. doi: 10.1002/hep.23775. PMID: 20583214.
49. Kalambokis GN, Christodoulou D, Baltayiannis G, Christou L. Propranolol use beyond 6 months increases mortality in patients with Child-Pugh C cirrhosis and ascites. Hepatology. 2016 Nov;64(5):1806-1808. doi: 10.1002/hep.28575. Epub 2016 Jun 1. PMID: 27016449.
50. Mandorfer M, Bota S, Schwabl P, Bucsics T, Pfisterer N, Kruzik M, et al. Nonselective β blockers increase risk for hepatorenal syndrome and death in patients with cirrhosis and spontaneous bacterial peritonitis. Gastroenterology. 2014 Jun;146(7):1680-90.e1. doi: 10.1053/j.gastro.2014.03.005. Epub 2014 Mar 12. PMID: 24631577.
1. Téllez L, Ibáñez-Samaniego L, Pérez Del Villar C, Yotti R, Martínez J, Carrión L, et al. Non-selective beta-blockers impair global circulatory homeostasis and renal function in cirrhotic patients with refractory ascites. J Hepatol. 2020 Dec;73(6):1404-1414. doi: 10.1016/j.jhep.2020.05.011. Epub 2020 May 21. PMID: 32446716.
2. Alvarado-Tapias E, Ardevol A, Garcia-Guix M, Montañés R, Pavel O, Cuyas B, et al. Short-term hemodynamic effects of β-blockers influence survival of patients with decompensated cirrhosis. J Hepatol. 2020 Oct;73(4):829-841. doi: 10.1016/j.jhep.2020.03.048. Epub 2020 Apr 13. PMID: 32298768.
3. Giannelli V, Roux O, Laouénan C, Manchon P, Ausloos F, Bachelet D, et al. Impact of cardiac function, refractory ascites and beta blockers on the outcome of patients with cirrhosis listed for liver transplantation. J Hepatol. 2020 Mar;72(3):463-471. doi: 10.1016/j.jhep.2019.10.002. Epub 2019 Oct 14. PMID: 31622697.
4. Tergast TL, Kimmann M, Laser H, Gerbel S, Manns MP, Cornberg M, et al. Systemic arterial blood pressure determines the therapeutic window of non-selective beta blockers in decompensated cirrhosis. Aliment Pharmacol Ther. 2019 Sep;50(6):696-706. doi: 10.1111/apt.15439. Epub 2019 Aug 2. PMID: 31373713.
5. Njei B, McCarty TR, Garcia-Tsao G. Beta-blockers in patients with cirrhosis and ascites: type of beta-blocker matters. Gut. 2016 Aug;65(8):1393-4. doi: 10.1136/gutjnl-2016-312129. Epub 2016 May 20. PMID: 27207973.
6. Téllez L, Albillos A. Non-selective beta-blockers in patients with ascites: the complex interplay among the liver, kidney, and heart. Liver Int. 2022 Jan 20. doi: 10.1111/liv.15166. Epub ahead of print. PMID: 35051310.
7. Bai M, Qi XS, Yang ZP, Yang M, Fan DM, Han GH. TIPS improves liver transplantation-free survival in cirrhotic patients with refractory ascites: an updated meta-analysis. World J Gastroenterol. 2014 Mar 14;20(10):2704-14. doi: 10.3748/wjg.v20.i10.2704. PMID: 24627607; PMCID: PMC3949280.
8. Bureau C, Thabut D, Oberti F, Dharancy S, Carbonell N, Bouvier A, et al. Transjugular Intrahepatic Portosystemic Shunts With Covered Stents Increase Transplant-Free Survival of Patients With Cirrhosis and Recurrent Ascites. Gastroenterology. 2017 Jan;152(1):157-163. doi: 10.1053/j.gastro.2016.09.016. Epub 2016 Sep 20.
9. Salerno F, Cammà C, Enea M, Rössle M, Wong F. Transjugular intrahepatic portosystemic shunt for refractory ascites: a meta-analysis of individual patient data. Gastroenterology. 2007 Sep;133(3):825-34. doi: 10.1053/j.gastro.2007.06.020. Epub 2007 Jun 20.
10. Villanueva C, Colomo A, Bosch A, Concepción M, Hernandez-Gea V, Aracil C, et al. Transfusion strategies for acute upper gastrointestinal bleeding. N Engl J Med. 2013 Jan 3;368(1):11-21. doi: 10.1056/NEJMoa1211801.
11. Lisman T, Hernandez-Gea V, Magnusson M, Roberts L, Stanworth S, Thachil J, et al. The concept of rebalanced hemostasis in patients with liver disease: Communication from the ISTH SSC working group on hemostatic management of patients with liver disease. J Thromb Haemost. 2021 Apr;19(4):1116-1122. doi: 10.1111/jth.15239. PMID: 33792172; PMCID: PMC8252070.
12. Northup PG, Lisman T, Roberts LN. Treatment of bleeding in patients with liver disease. J Thromb Haemost. 2021 Jul;19(7):1644-1652. doi: 10.1111/jth.15364. Epub 2021 Jun 6. PMID: 33974330; PMCID: PMC8362012.
13. Rassi AB, d'Amico EA, Tripodi A, da Rocha TRF, Migita BY, Ferreira CM, et al. Fresh frozen plasma transfusion in patients with cirrhosis and coagulopathy: Effect on conventional coagulation tests and thrombomodulin-modified thrombin generation. J Hepatol. 2020 Jan;72(1):85-94. doi: 10.1016/j.jhep.2019.09.008. Epub 2019 Sep 16. PMID: 31536747.
14. Mohanty A, Kapuria D, Canakis A, Lin H, Amat MJ, Rangel Paniz G et al. Fresh frozen plasma transfusion in acute variceal haemorrhage: Results from a multicentre cohort study. Liver Int. 2021 Aug;41(8):1901-1908. doi: 10.1111/liv.14936. Epub 2021 May 24. PMID: 33969607.
15. von Meijenfeldt FA, van den Boom BP, Adelmeijer J, Roberts LN, Lisman T, Bernal W. Prophylactic fresh frozen plasma and platelet transfusion have a prothrombotic effect in patients with liver disease. J Thromb Haemost. 2021 Mar;19(3):664-676. doi: 10.1111/jth.15185. Epub 2020 Dec 25. PMID: 33219597; PMCID: PMC7986736.
16. HALT-IT Trial Collaborators. Effects of a high-dose 24-h infusion of tranexamic acid on death and thromboembolic events in patients with acute gastrointestinal bleeding (HALT-IT): an international randomised, double-blind, placebo-controlled trial. Lancet. 2020 Jun 20;395(10241):1927-1936. doi: 10.1016/S0140-6736(20)30848-5. PMID: 32563378; PMCID: PMC7306161.
17. Bendtsen F, D'Amico G, Rusch E, de Franchis R, Andersen PK, Lebrec D, et al. Effect of recombinant Factor VIIa on outcome of acute variceal bleeding: an individual patient based meta-analysis of two controlled trials. J Hepatol. 2014 Aug;61(2):252-9. doi: 10.1016/j.jhep.2014.03.035. Epub 2014 Apr 5. PMID: 24713188.
18. Chaudhuri D, Bishay K, Tandon P, Trivedi V, James PD, Kelly EM, Thavorn K, Kyeremanteng K. Prophylactic endotracheal intubation in critically ill patients with upper gastrointestinal bleed: A systematic review and meta-analysis. JGH Open. 2019 May 24;4(1):22-28. doi: 10.1002/jgh3.12195. PMID: 32055693; PMCID: PMC7008165
19. Martínez J, Hernández-Gea V, Rodríguez-de-Santiago E, Téllez L, Procopet B, Giráldez Á, et al. Bacterial infections in patients with acute variceal bleeding in the era of antibiotic prophylaxis. J Hepatol. 2021 Aug;75(2):342-350. doi: 10.1016/j.jhep.2021.03.026. Epub 2021 Jun 12. PMID: 33845059.
20. Nardelli S, Gioia S, Ridola L, Farcomeni A, Merli M, Riggio O. Proton Pump Inhibitors Are Associated With Minimal and Overt Hepatic Encephalopathy and Increased Mortality in Patients With Cirrhosis. Hepatology. 2019 Aug;70(2):640-649. doi: 10.1002/hep.30304. Epub 2019 Mar 4. PMID: 30289992.
21. De Roza MA, Kai L, Kam JW, Chan YH, Kwek A, Ang TL, et al. Proton pump inhibitor use increases mortality and hepatic decompensation in liver cirrhosis. World J Gastroenterol. 2019 Sep 7;25(33):4933-4944. doi: 10.3748/wjg.v25.i33.4933. PMID: 31543684; PMCID: PMC6737311.
22. Tsai MH, Huang HC, Peng YS, Chen YC, Tian YC, Yang CWet al. Nutrition Risk Assessment Using the Modified NUTRIC Score in Cirrhotic Patients with Acute Gastroesophageal Variceal Bleeding: Prevalence of High Nutrition Risk and its Independent Prognostic Value. Nutrients. 2019 Sep 9;11(9):2152. doi: 10.3390/nu11092152. PMID: 31505759; PMCID: PMC6769743.
23. Lo GH, Lin CW, Tai CM, Perng DS, Chen IL, Yeh JH, et al. A prospective, randomized trial of thrombin versus cyanoacrylate injection in the control of acute gastric variceal hemorrhage. Endoscopy. 2020 Jul;52(7):548-555. doi: 10.1055/a-1127-3170. Epub 2020 Apr 14. PMID: 32289853.
24. Bhurwal A, Makar M, Patel A, Mutneja H, Goel A, Bartel M, et al. Safety and Efficacy of Thrombin for Bleeding Gastric Varices: A Systematic Review and Meta-Analysis. Dig Dis Sci. 2021 Mar 17. doi: 10.1007/s10620-021-06915-5. Epub ahead of print. PMID: 33728506.
25. Mohan BP, Chandan S, Khan SR, Kassab LL, Trakroo S, Ponnada S, Asokkumar R, Adler DG. Efficacy and safety of endoscopic ultrasound-guided therapy versus direct endoscopic glue injection therapy for gastric varices: systematic review and meta-analysis. Endoscopy. 2020 Apr;52(4):259-267. doi: 10.1055/a-1098-1817. Epub 2020 Feb 6. PMID: 32028533.
26. Henry Z, Patel K, Patton H, Saad W. AGA Clinical Practice Update on Management of Bleeding Gastric Varices: Expert Review. Clin Gastroenterol Hepatol. 2021 Jun;19(6):1098-1107.e1. doi: 10.1016/j.cgh.2021.01.027. Epub 2021 Jan 22. PMID: 33493693.
27. Ibrahim M, El-Mikkawy A, Abdel Hamid M, Abdalla H, Lemmers A, Mostafa I, et al. Early application of haemostatic powder added to standard management for oesophagogastric variceal bleeding: a randomised trial. Gut. 2019 May;68(5):844-853. doi: 10.1136/gutjnl-2017-314653. Epub 2018 May 5. PMID: 29730601; PMCID: PMC6580783.
28. Chen PH, Chen WC, Hou MC, Liu TT, Chang CJ, Liao WC, et al. Delayed endoscopy increases re-bleeding and mortality in patients with hematemesis and active esophageal variceal bleeding: a cohort study. J Hepatol. 2012 Dec;57(6):1207-13. doi: 10.1016/j.jhep.2012.07.038. Epub 2012 Aug 8. PMID: 22885718.
29. Lau JYW, Yu Y, Tang RSY, Chan HCH, Yip HC, Chan SM, et al. Timing of Endoscopy for Acute Upper Gastrointestinal Bleeding. N Engl J Med. 2020 Apr 2;382(14):1299-1308. doi: 10.1056/NEJMoa1912484. PMID: 32242355.
30. Escorsell À, Pavel O, Cárdenas A, Morillas R, Llop E, Villanueva C, et al. Esophageal balloon tamponade versus esophageal stent in controlling acute refractory variceal bleeding: A multicenter randomized, controlled trial. Hepatology. 2016 Jun;63(6):1957-67. doi: 10.1002/hep.28360. Epub 2016 Jan 14. PMID: 26600191.
31. Rodrigues SG, Cárdenas A, Escorsell À, Bosch J. Balloon Tamponade and Esophageal Stenting for Esophageal Variceal Bleeding in Cirrhosis: A Systematic Review and Meta-analysis. Semin Liver Dis. 2019 May;39(2):178-194. doi: 10.1055/s-0039-1678726. Epub 2019 Mar 25. PMID: 30912098.
32. Walter A, Rudler M, Olivas P, Moga L, Trépo E, Robic MA, et al. Combination of Model for End-Stage Liver Disease and Lactate Predicts Death in Patients Treated With Salvage Transjugular Intrahepatic Portosystemic Shunt for Refractory Variceal Bleeding. Hepatology. 2021 Oct;74(4):2085-2101. doi: 10.1002/hep.31913. Epub 2021 Jul 19. PMID: 34018627.
33. Monescillo A, Martínez-Lagares F, Ruiz-del-Arbol L, Sierra A, Guevara C, Jiménez E, et al. Influence of portal hypertension and its early decompression by TIPS placement on the outcome of variceal bleeding. Hepatology. 2004 Oct;40(4):793-801. doi: 10.1002/hep.20386. PMID: 15382120.
34. García-Pagán JC, Caca K, Bureau C, Laleman W, Appenrodt B, Luca A, et al. Early use of TIPS in patients with cirrhosis and variceal bleeding. N Engl J Med. 2010 Jun 24;362(25):2370-9. doi: 10.1056/NEJMoa0910102. PMID: 20573925.
35. Garcia-Pagán JC, Di Pascoli M, Caca K, Laleman W, Bureau C, Appenrodt B, et al. Use of early-TIPS for high-risk variceal bleeding: results of a post-RCT surveillance study. J Hepatol. 2013 Jan;58(1):45-50. doi: 10.1016/j.jhep.2012.08.020. Epub 2012 Aug 30. PMID: 22940408.
36. Hernández-Gea V, Procopet B, Giráldez Á, Amitrano L, Villanueva C, Thabut D, et al. Preemptive-TIPS Improves Outcome in High-Risk Variceal Bleeding: An Observational Study. Hepatology. 2019 Jan;69(1):282-293. doi: 10.1002/hep.30182. Epub 2018 Dec 10. PMID: 30014519.
37. Lv Y, Zuo L, Zhu X, Zhao J, Xue H, Jiang Z, et al. Identifying optimal candidates for early TIPS among patients with cirrhosis and acute variceal bleeding: a multicentre observational study. Gut. 2019 Jul;68(7):1297-1310. doi: 10.1136/gutjnl-2018-317057. Epub 2018 Nov 10. PMID: 30415233.
38. Lv Y, Yang Z, Liu L, Li K, He C, Wang Z, et al. Early TIPS with covered stents versus standard treatment for acute variceal bleeding in patients with advanced cirrhosis: a randomised controlled trial. Lancet Gastroenterol Hepatol. 2019 Aug;4(8):587-598. doi: 10.1016/S2468-1253(19)30090-1. Epub 2019 May 29. PMID: 31153882.
39. Nicoară-Farcău O, Han G, Rudler M, Angrisani D, Monescillo A, Torres F, et al. Effects of Early Placement of Transjugular Portosystemic Shunts in Patients With High-Risk Acute Variceal Bleeding: a Meta-analysis of Individual Patient Data. Gastroenterology. 2021 Jan;160(1):193-205.e10. doi: 10.1053/j.gastro.2020.09.026. Epub 2020 Sep 24. PMID: 32980344.
40. Trebicka J, Gu W, Ibáñez-Samaniego L, Hernández-Gea V, Pitarch C, Garcia E, et al. Rebleeding and mortality risk are increased by ACLF but reduced by pre-emptive TIPS. J Hepatol. 2020 Nov;73(5):1082-1091. doi: 10.1016/j.jhep.2020.04.024. Epub 2020 Apr 24. PMID: 32339602.